



Media Contact: Corporate Communications Department Tel +81-3-3278-2037

News Release

The Settlement of Protonix® Patent Litigation in the U.S.

Osaka, Japan, June 13, 2013 --- Takeda Pharmaceutical Company Limited (Takeda) today announced \$2.15 billion settlement reached with Teva Pharmaceutical Industries Limited (Teva) and Sun Pharmaceutical Industries Limited (Sun) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix (generic name: pantoprazole) in the United States. In the litigation, Pfizer Inc. (Pfizer) and Nycomed (now part of Takeda) sought to enforce the patent No. 4,758,579, which is owned by Takeda and is licensed exclusively to Wyeth, a Pfizer's subsidiary, in the United States.

Pfizer and Takeda will share the proceeds of the settlement, and, it should be noted that Takeda's acquisition of Nycomed in 2011 excluded proceeds from this litigation and, therefore, all the proceeds to be received by Takeda from Teva and Sun will be forwarded to the former owners of Nycomed.

Under the terms of the settlement, Teva and Sun will pay a total of \$2.15 billion, which consists of \$1.6 billion from Teva and \$550 million from Sun respectively, to compensate Wyeth and Takeda for the damages they suffered when Teva and Sun launched "at-risk" generic versions of Protonix prior to the January 2011 expiry of the said patent for pantoprazole. As part of the settlement, both Teva and Sun have admitted that their sales of generic pantoprazole infringed the patent that was held valid by the court.

###

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.